Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Rifaximin, a non-systemic antibiotic, is efficacious for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). Given the emerging association between the gut microbiota and IBS, this study examined potential effects of rifaximin on the gastrointestinal microbial community in patients with IBS-D. TARGET 3 was a randomised, double-blind, placebo-controlled, phase 3 study. Patients with IBS-D initially received open-label rifaximin 550 mg 3 times daily (TID) for 2 weeks. Patients who responded to the initial treatment and then relapsed were randomised to receive 2 repeat courses of rifaximin 550 mg TID or placebo for 2 weeks, with each course separated by 10 weeks. Stool samples were collected at the beginning and end of open-label treatment, at the beginning and end of the first double-blind treatment, and at the end of the study. As a secondary analysis to the TARGET 3 trial, the composition and diversity of the gut microbiota were assessed, from a random subset of patients, using variable 4 hypervariable region 16S ribosomal RNA gene sequencing. Samples from 103 patients were included. After open-label rifaximin treatment for 2 weeks, 7 taxa (e.g. Peptostreptococcaceae, Verrucomicrobiaceae, Enterobacteriaceae) had significantly lower relative abundance at a 10% false discovery rate threshold. The effects of rifaximin were generally short-term, as there was little evidence of significantly different changes in taxa relative abundance at the end of the study (up to 46 weeks) versus baseline. The results suggest that rifaximin has a modest, largely transient effect across a broad range of stool microbes. Future research may determine whether the taxa affected by rifaximin are causally linked to IBS-D. ClinicalTrials.gov identifier number: NCT01543178.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Self-citationRifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036 · cited 2×
“The efficacy and safety of rifaximin, approved for the treatment of adults with diarrhoea-predominant IBS (IBS-D), have been demonstrated in various clinical studies.(27-32) In 2 identically designed, double-blind, phase 3 studies (Targeted, non-systemic Antibiotic Rifaximin Gutselective Evaluation of Treatment for IB…”
BackgroundSelf-citationDiarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum
Guilarte, M., Santos, J., de Torres, I., Alonso, C., Vicario, M., Ramos, L., Martinez, C., Casellas, F., Saperas, E., & Malagelada, J. R. (2007) · Gut · doi:10.1136/gut.2006.100594 · Cited by 385 · cited 1×
“psychiatric conditions).(3-12) The role of the GI microbial community (gut microbiota) cannot be overlooked, given evidence supporting an association between enteric infections and post-infectious IBS development,(13,14) alterations in the gut microbiota in patients with IBS versus healthy individuals,(15-18) and gut…”
BackgroundIntestinal membrane permeability and hypersensitivity in the irritable bowel syndrome
Zhou, Q., Zhang, B., & Verne, N. G. (2009) · Pain · doi:10.1016/j.pain.2009.06.017 · Cited by 373 · cited 1×
“psychiatric conditions).(3-12) The role of the GI microbial community (gut microbiota) cannot be overlooked, given evidence supporting an association between enteric infections and post-infectious IBS development,(13,14) alterations in the gut microbiota in patients with IBS versus healthy individuals,(15-18) and gut…”
BackgroundLembo, A., Pimentel, M., Rao, S. S., Schoenfeld, P., Cash, B., Weinstock, L. B., Paterson, C., Bortey, E., & Forbes, W. P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.003 · Cited by 310 · cited 4×
“1).(32) Non-responders to open-label rifaximin were withdrawn from the study after V4.”
BackgroundMethodInfluentialSelf-citationXu, D., Gao, J., Gillilland, M., Wu, X., Song, I., Kao, J. Y., & Owyang, C. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.10.026 · Cited by 271 · cited 1×
“in the ileum, but also decreased stress-induced mucosal inflammation and normalised visceral hypersensitivity in animal studies.(26) Further, rifaximin altered bacterial adhesion to epithelial cells in vitro, thus affecting the ability of some bacterial species to colonise the GI tract.”
BackgroundA Molecular Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel Syndrome
Codling, C., O’Mahony, L., Shanahan, F., Quigley, E. M. M., & Marchesi, J. R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0934-x · Cited by 243
Hungin, A. P. S., Mulligan, C., Pot, B., Whorwell, P., Agréus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J.-M., Rubin, G., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12460 · Cited by 212
Differential Effects of Antibiotic Therapy on the Structure and Function of Human Gut Microbiota
Pérez-Cobas, A. E., Artacho, A., Knecht, H., Ferrús, M. L., Friedrichs, A., Ott, S. J., Moya, A., Latorre, A., & Gosalbes, M. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080201 · Cited by 212 · cited 1×
“sity of the GI bacterial community fluctuated following antibiotic therapy.(34) Previous studies(35,36)”
BackgroundBiostructure of Fecal Microbiota in Healthy Subjects and Patients With Chronic Idiopathic Diarrhea
Swidsinski, A., Loening–Baucke, V., Verstraelen, H., Osowska, S., & Doerffel, Y. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.04.017 · Cited by 178
Cited by
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
Self-citationMayer, E. A., Nance, K., & Chen, S. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042320-014032 · Cited by 813
Gut liver brain axis in diseases: the implications for therapeutic interventions
Yan, M., Man, S., Sun, B., Ma, L., Guo, L., Huang, L., & Gao, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01673-4 · Cited by 287
The gut microbiome and irritable bowel syndrome
Menees, S., & Chey, W. (2018) · F1000Research · doi:10.12688/f1000research.14592.1 · Cited by 159
“Overall, the short-term adverse event profile with rifaximin is similar to that of placebo, and stool analyses from the Target 3 study demonstrate short-term depression of diversity and richness 48 across a broad range of microbes which was largely reversed at study end.”
BackgroundSelf-citationThe challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D., Vierling, J. M., Adams, D., Alpini, G., Banales, J. M., Beuers, U., Björnsson, E., Bowlus, C., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102328 · Cited by 114
Metadata
- Authors
- Fodor, A. A., Pimentel, M., Chey, W. D., Lembo, A., Golden, P. L., Israel, R. J., & Carroll, I. M.
- Venue
- Gut Microbes
- Publisher
- Informa UK Limited
- Published
- 2018-07-18
- Volume
- 10
- Issue
- 1
- Pages
- 22-33
- ISSN
- 1949-0976 (ISSN-L)
- 1949-0984
- OpenAlex
- W2802840820
- Cited by
- 84
- References
- 13
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. https://app.cochat.ai/papers/10.1080/19490976.2018.1460013
- The paper
- Fodor, A. A., Pimentel, M., Chey, W. D., Lembo, A., Golden, P. L., Israel, R. J., & Carroll, I. M. (2019). Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes. https://doi.org/10.1080/19490976.2018.1460013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.